Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FYB.F
- Price
- 21.30
- Stock movement down
- -0.55 (-2.52%)
- Company name
- Formycon AG
- Exchange
- (F ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 376.25M
- Ent value
- 736.83M
- Price/Sales
- -
- Price/Book
- 0.75
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 44.35%
- 1 year return
- -53.90%
- 3 year return
- -30.81%
- 5 year return
- -0.46%
- 10 year return
- -1.82%
Last updated: 2025-04-12
DIVIDENDS
FYB.F does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 51.81 |
| EV to EBITDA | 101.46 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.75 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.66M |
| EPS (TTM) | - |
| FCF per share (TTM) | -0.80 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | 0.00 |
| Net income (TTM) | 0.00 |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 27.04M |
| Net receivables | 11.61M |
| Total current assets | 67.15M |
| Goodwill | 44.53M |
| Intangible assets | 508.40M |
| Property, plant and equipment | 20.09M |
| Total assets | 890.36M |
| Accounts payable | 16.32M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 69.31M |
| Total liabilities | 387.61M |
| Shareholder's equity | 502.75M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.50M |
| Capital expenditures (TTM) | 379.50K |
| Free cash flow (TTM) | -12.88M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | -2.56% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 22.40 |
| Daily high | 22.40 |
| Daily low | 21.30 |
| Daily Volume | 0K |
| All-time high | 91.70 |
| 1y analyst estimate | 54.75 |
| Beta | 0.83 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 23 Apr 2025 |
Downside potential
Loading...
Downside potential data
| FYB.F | S&P500 | |
| Current price drop from All-time high | -76.77% | -14.41% |
| Highest price drop | -81.62% | -56.47% |
| Date of highest drop | 24 Sep 2012 | 9 Mar 2009 |
| Avg drop from high | -30.18% | -11.07% |
| Avg time to new high | 77 days | 12 days |
| Max time to new high | 992 days | 1805 days |
COMPANY DETAILS
Marketcap
376.25M
Marketcap category
Small-cap
Description
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Employees
239
Website
Investor relations
-
SEC filings
CEO
Country
Germany
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Amid a challenging landscape marked by fresh U.S. trade tariffs and fluctuating consumer confidence, European markets have experienced volatility, with the STOXX Europe 600 Index ending the week lower...
April 4, 2025
As European markets navigate the challenges of fresh U.S. trade tariffs and a mixed economic outlook, investors are increasingly focusing on companies that demonstrate resilience and potential for gro...
March 31, 2025
As European markets grapple with the impact of new U.S. trade tariffs and mixed economic signals, including a recent dip in consumer confidence, investors are closely watching the tech sector for pote...
March 31, 2025
Formycon ( ETR:FYB ) Full Year 2024 Results Key Financial Results Revenue: €69.7m (down 10% from FY 2023). Net loss...
March 30, 2025
As global markets continue to react positively to political developments and economic indicators, major U.S. stock indices have reached record highs, driven by optimism surrounding potential trade dea...
January 31, 2025
As global markets continue to react positively to the Trump administration's emerging policies, with U.S. stocks reaching record highs and growth stocks outperforming value shares, investors are incre...
January 29, 2025
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration of ...
January 13, 2025
Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...
January 8, 2025
As we step into January 2025, global markets are witnessing a mixed sentiment with U.S. consumer confidence on the decline and key indices such as the Nasdaq Composite showing moderate gains amidst a ...
January 2, 2025
In a week marked by cautious Federal Reserve commentary and political uncertainty, global markets have experienced broad-based declines, with U.S. stocks facing significant challenges. Amid these turb...
December 25, 2024
Next page